scholarly journals Brazilian Green Propolis Protects against Retinal Damage In Vitro and In Vivo

2006 ◽  
Vol 3 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Yuta Inokuchi ◽  
Masamitsu Shimazawa ◽  
Yoshimi Nakajima ◽  
Shinsuke Suemori ◽  
Satoshi Mishima ◽  
...  

Propolis, a honeybee product, has gained popularity as a food and alternative medicine. Its constituents have been shown to exert pharmacological (anticancer, antimicrobial and anti-inflammatory) effects. We investigated whether Brazilian green propolis exerts neuroprotective effects in the retinain vitroand/orin vivo.In vitro, retinal damage was induced by 24 h hydrogen peroxide (H2O2) exposure, and cell viability was measured by Hoechst 33342 and YO-PRO-1 staining or by a resazurin–reduction assay. Propolis inhibited the neurotoxicity and apoptosis induced in cultured retinal ganglion cells (RGC-5, a rat ganglion cell line transformed using E1A virus) by 24 h H2O2 exposure. Propolis also inhibited the neurotoxicity induced in RGC-5 cultures by staurosporine. Regarding the possible underlying mechanism, in pig retina homogenates propolis protected against oxidative stress (lipid peroxidation), as also did trolox (water-soluble vitamin E). In micein vivo, propolis (100 mg kg−1; intraperitoneally administered four times) reduced the retinal damage (decrease in retinal ganglion cells and in thickness of inner plexiform layer) induced by intravitrealin vivo N-methyl-d-aspartate injection. These findings indicate that Brazilian green propolis has neuroprotective effects against retinal damage bothin vitroandin vivo, and that a propolis-induced inhibition of oxidative stress may be partly responsible for these neuroprotective effects.

2016 ◽  
Vol 11 (1) ◽  
Author(s):  
Byung-Jin Kim ◽  
Sean M. Silverman ◽  
Yang Liu ◽  
Robert J. Wordinger ◽  
Iok-Hou Pang ◽  
...  

2009 ◽  
Vol 247 (10) ◽  
pp. 1353-1360 ◽  
Author(s):  
Akiyasu Kanamori ◽  
Maiko Naka ◽  
Masahide Fukuda ◽  
Makoto Nakamura ◽  
Akira Negi

2020 ◽  
Vol 104 ◽  
pp. 101747 ◽  
Author(s):  
Yun Ou-Yang ◽  
Zheng-Li Liu ◽  
Chun-Long Xu ◽  
Jia-Liang Wu ◽  
Jun Peng ◽  
...  

2009 ◽  
Vol 1251 ◽  
pp. 269-275 ◽  
Author(s):  
Masamitsu Shimazawa ◽  
Yoshimi Nakajima ◽  
Yukihiko Mashima ◽  
Hideaki Hara

2009 ◽  
Vol 88 (3) ◽  
pp. 535-541 ◽  
Author(s):  
Akiyasu Kanamori ◽  
Maiko Naka ◽  
Masahide Fukuda ◽  
Makoto Nakamura ◽  
Akira Negi

2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
Bikun Xian ◽  
Ziming Luo ◽  
Kaijing Li ◽  
Kang Li ◽  
Mingjun Tang ◽  
...  

We investigated the efficacy of the immunosuppressants rapamycin (RAP) and dexamethasone (DEX) in improving the survival of retinal organoids after epiretinal transplantation. We first compared the immunosuppressive abilities of DEX and RAP in activated microglia in an in vitro setting. Following this, we used immunofluorescence, real-time polymerase chain reaction, and flow cytometry to investigate the effects of DEX and RAP on cells in the retinal organoids. Retinal organoids were then seeded onto poly(lactic-co-glycolic) acid (PLGA) scaffolds and implanted into rhesus monkey eyes (including a healthy individual and three monkeys with chronic ocular hypertension (OHT) induction) and subjected to different post-operative immunosuppressant treatments; 8 weeks after the experiment, histological examinations were carried out to assess the success of the different treatments. Our in vitro experiments indicated that both DEX and RAP treatments were equally effective in suppressing microglial activity. Although both immunosuppressants altered the morphologies of cells in the retinal organoids and caused a slight decrease in the differentiation of cells into retinal ganglion cells, the organoid cells retained their capacity to grow and differentiate into retinal tissues. Our in vivo experiments indicate that the retinal organoid can survive and differentiate into retinal tissues in a healthy rhesus monkey eye without immunosuppressive treatment. However, the survival and differentiation of these organoids in OHT eyes was successful only with the DEX treatment. RAP treatment was ineffective in preventing immunological rejection, and the retinal organoid failed to survive until the end of 8 weeks. DEX is likely a promising immunosuppressant to enhance the survival of epiretinal implants.


Sign in / Sign up

Export Citation Format

Share Document